title: Re: Letter written in reaction to "Pregabalin prescriptions in the United Kingdom: a drug utilisation study of The Health Improvement Network (THIN) primary care database", by Pottegård et al. - The authors (Asomaning et al.) respond.
authors.affiliation: Department of Epidemiology, Pfizer Inc, New York, NY, USA. kofi.asomaning@pfizer.com.
authors.forename: K
authors.initials: K
authors.lastname: Asomaning
authors.affiliation: Department of Epidemiology, Pfizer Inc, New York, NY, USA.
authors.forename: S
authors.initials: S
authors.lastname: Abramsky
authors.affiliation: Department of Epidemiology, Pfizer Inc, New York, NY, USA.
authors.forename: Q
authors.initials: Q
authors.lastname: Liu
authors.affiliation: Department of Epidemiology, Pfizer Inc, New York, NY, USA.
authors.forename: X
authors.initials: X
authors.lastname: Zhou
authors.affiliation: Department of Epidemiology, Pfizer Inc, New York, NY, USA.
authors.forename: R E
authors.initials: RE
authors.lastname: Sobel
authors.affiliation: Department of Medical Affairs, Pfizer Inc, New York, NY, USA.
authors.forename: S
authors.initials: S
authors.lastname: Watt
mesh_terms: D004363:Drug Utilization; D006801:Humans; D000069583:Pregabalin; D011320:Primary Health Care; D006113:United Kingdom; D014956:Writing
chemical_list: D000069583:Pregabalin